Loading...
•
Mar 31, 2024
West Pharma Q1 2024 Earnings Report
West Pharma's first quarter results were announced, showing a slight decrease in net sales and a decline in reported EPS, while reaffirming full-year net sales guidance and raising full-year adjusted EPS guidance.
Key Takeaways
West Pharmaceutical Services reported a 3.0% decrease in net sales to $695.4 million and a 16.2% decline in reported diluted EPS to $1.55 for the first quarter of 2024. The company reaffirmed its full-year net sales guidance of $3.000 billion to $3.025 billion and raised its full-year adjusted diluted EPS guidance to a new range of $7.63 to $7.88.
Net sales decreased by 3.0% to $695.4 million, with a similar decline in organic net sales.
Reported diluted EPS decreased by 16.2% to $1.55, while adjusted diluted EPS decreased by 21.2% to $1.56.
Full-year net sales guidance reaffirmed in the range of $3.000 billion to $3.025 billion.
Full-year adjusted diluted EPS guidance raised to a new range of $7.63 to $7.88.
West Pharma
West Pharma
West Pharma Revenue by Segment
Revenue by Segment
Proprietary Products Revenue
CapyFin.comContract-Manufactured Products Revenue
CapyFin.com Forward Guidance
The Company is reaffirming full-year 2024 financial guidance of net sales in a range of $3.000 billion to $3.025 billion and raising full-year 2024 financial guidance of adjusted-diluted EPS to a new range of $7.63 to $7.88.
Positive Outlook
- Full-year 2024 net sales guidance reaffirmed in a range of $3.000 billion to $3.025 billion.
- Organic net sales growth is expected to be approximately 2% to 3%.
- Full-year 2024 adjusted-diluted EPS guidance raised to a new range of $7.63 to $7.88.
- Updated guidance includes EPS of $0.15 associated with first-quarter 2024 tax benefits from stock-based compensation.
- Full-year 2024 capital spending guidance is unchanged and is expected to be $350 million.
Challenges Ahead
- Net sales guidance includes an estimated full-year 2024 headwind of approximately $8.0 million based on current foreign currency exchange rates.
- Full-year adjusted-diluted EPS guidance range includes an estimated headwind of approximately $0.04 based on current foreign currency exchange rates, which is an increase from prior guidance of $0.02.
- For the remaining quarters of the year, our EPS guidance range assumes a tax rate of 22.5% and does not include potential tax benefits from stock-based compensation.
- Net sales of $695.4 million declined 3.0%; organic net sales also declined by 3.0%.
- Reported-diluted EPS of $1.55 declined by 16.2%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income